Acquisition - August 16, 2016
Mylan completes acquisition of Meda
Earlier this month Mylan announced that it has completed the settlement of its recommended public offer to the shareholders of Meda Aktiebolag to tender all their shares in Meda to Mylan. The offer was accepted by shareholders holding approximately 94% of the total number of outstanding shares and votes in Meda, as of July 29, 2016. […]
Acquisition - July 10, 2016
BMS acquires Cormorant Pharmaceuticals
Bristol-Myers Squibb has acquired all of the outstanding capital stock of Cormorant, a private, Stockholm, Sweden-based pharmaceutical company focused on the development of therapies for cancer and rare diseases. The acquisition gives Bristol-Myers Squibb full rights to Cormorant’s HuMax-IL8 antibody program and the lead candidate HuMax-IL8, a Phase 1/2 monoclonal antibody targeted against interleukin-8 (IL-8) […]
Acquisition - June 9, 2016
Probi acquires Nutraceutix
Probi to acquire Nutraceutix, strongly expanding its North American presence and capabilities, and announces rights issue of ca SEK 600 million. Swedish Probi has announced that its US subsidiary Probi USA has signed an asset purchase agreement under which Probi will acquire the operations of the US probiotic company TNTGamble, doing business as Nutraceutix, for a preliminary cash purchase price […]
Acquisition - May 17, 2016
Biovica acquires cSens
Biovica has acquired cSens, a company that has developed a PCR-based platform for the analysis of serum thymidine kinase (TK) enzyme activity, which correspond to tumor proliferation and cancer aggressiveness. The cSens technology complements Biovica’s current TK assay DiviTum ™, which is currently included in clinical studies with leading cancer institutes throughout the world. The […]
Acquisition - May 4, 2016
Senzime acquires Acacia Designs
Swedish Senzime has entered into an agreement to acquire Acacia Designs BV, an international development company within anesthesia monitoring. The acquisition will be financed by 16,076,730 newly issued shares in Senzime through a non-cash issue. After the acquisition, Acacia’s shareholders will own 50 percent of the shares in Senzime. In connection with the acquisition, a […]
Acquisition - April 20, 2016
Diamyd increases investment in Cellaviva
Diamyd Medical has announced that the company has increased its investment in the associated company Cellaviva with an additional SEK 1.3 million. The investment is made within the framework of a convertible loan of SEK 2.7 million, mainly directed at existing shareholders. The convertible loan will, among others, be used to finance Cellaviva’s development of existing service […]
